Market Summary
USD193.56-1.34
Delayed-0.69%
CRL Stock Price
CRL RSI Chart
CRL Valuation
CRL Price/Sales (Trailing)
CRL Profitability
CRL Fundamentals
CRL Revenue
CRL Earnings
Price Action
52 Week Range
181.36308.15
(Low)(High)
Last 7 days
-10.9%
Last 30 days
-23.1%
Last 90 days
-10.8%
Trailing 12 Months
-24.8%
CRL Financial Health
CRL Investor Care
Peers (Alternatives to Charles River Laboratories International)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
A | 40.4B | 6.8B | -13.31% | 3.22% | 32.19 | 5.89 | 8.37% | 3.64% |
IQV | 36.5B | 14.4B | -15.87% | -9.18% | 33.43 | 2.53 | 3.86% | 12.94% |
ILMN | 35.5B | 4.6B | 5.65% | -27.02% | -8.07 | 7.75 | 1.28% | -677.95% |
CRL | 9.9B | 4.0B | -23.12% | -24.82% | 20.28 | 2.48 | 12.31% | 24.36% |
| MID-CAP | ||||||||
MEDP | 5.7B | 1.5B | -22.25% | 21.52% | 23.09 | 3.88 | 27.80% | 34.93% |
SYNH | 3.5B | 5.4B | -2.51% | -56.11% | 13.26 | 0.66 | 3.46% | 13.48% |
ARWR | 2.6B | 278.3M | -26.82% | -37.82% | -16.79 | 9.32 | 92.72% | 15.56% |
NEO | 2.4B | 509.7M | 46.19% | 25.15% | -16.73 | 4.74 | 5.24% | -1628.17% |
| SMALL-CAP | ||||||||
AVXL | 744.4M | - | -10.86% | -12.11% | -14.87 | 291.16 | -34.21% | -22.31% |
CDXS | 271.1M | 138.6M | -29.13% | -76.08% | -8.07 | 1.96 | 32.30% | -57.86% |
PGEN | 224.8M | 80.7M | -30.82% | -43.30% | 7.94 | 4.15 | 13.30% | 130.72% |
SRNE | 143.9M | 60.3M | -71.28% | -88.95% | -0.29 | 2.39 | 17.51% | -38.93% |
PSNL | 135.5M | 65.0M | -20.46% | -63.49% | -1.2 | 2.08 | -23.92% | -73.73% |
Financials for Charles River Laboratories International
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 5.2% | 3,976 | 3,781 | 3,688 | 3,630 | 3,540 |
| S&GA Expenses | 9.1% | 665 | 610 | 574 | 614 | 620 |
| EBITDA | 21.8% | 986 | 809 | 814 | - | - |
| EBITDA Margin | 13.0% | 0.25* | 0.22* | 0.22* | - | - |
| Earnings Before Taxes | 29.6% | 623 | 481 | - | - | - |
| EBT Margin | 20.2% | 0.16* | 0.13* | 0.13* | - | - |
| Interest Expenses | 64.4% | 59.00 | 36.00 | 41.00 | 54.00 | 74.00 |
| Net Income | 11.4% | 486 | 436 | 443 | 422 | 391 |
| Net Income Margin | 6.0% | 0.12* | 0.12* | 0.12* | 0.12* | - |
| Free Cahsflow | 0.9% | 620 | 614 | 656 | 693 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 3.0% | 7,603 | 7,383 | 7,529 | 7,075 | 7,024 |
| Current Assets | 1.7% | 1,439 | 1,415 | 1,393 | 1,333 | 1,274 |
| Cash Equivalents | 20.8% | 234 | 194 | 200 | 242 | 241 |
| Inventory | -2.2% | 256 | 262 | 257 | 221 | 199 |
| Goodwill | 2.7% | 2,850 | 2,776 | 2,860 | 216 | 2,712 |
| Liabilities | -2.8% | 4,579 | 4,711 | 4,836 | 4,404 | 4,432 |
| Current Liabilities | 7.6% | 1,092 | 1,014 | 1,048 | 994 | 1,033 |
| Long Term Debt | -7.8% | 2,708 | 2,937 | 2,997 | 2,676 | 2,664 |
| LT Debt, Current | -100.0% | - | 0.00 | 0.00 | 0.00 | - |
| Shareholder's Equity | 13.3% | 2,976 | 2,627 | 2,653 | 2,615 | 2,535 |
| Retained Earnings | 12.0% | 1,433 | 1,280 | 1,183 | 1,074 | 981 |
| Additional Paid-In Capital | 1.4% | 1,805 | 1,781 | 1,761 | 1,745 | 1,718 |
| Accumulated Depreciation | - | 1,103 | - | - | - | - |
| Shares Outstanding | 0.1% | 51.00 | 51.00 | 51.00 | 51.00 | 50.00 |
| Minority Interest | -18.7% | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 0.9% | 620 | 614 | 656 | 693 | 761 |
| Share Based Compensation | 4.1% | 74.00 | 71.00 | 71.00 | 73.00 | 71.00 |
| Cashflow From Investing | 5.5% | -607 | -643 | -905 | -1,397 | -1,437 |
| Cashflow From Financing | -241.6% | -42.40 | -12.41 | 218 | 465 | 673 |
| Buy Backs | -0.3% | 39.00 | 39.00 | 39.00 | 39.00 | 41.00 |
Risks for CRL
What is the probability of a big loss on CRL?
45.8%
Probability that Charles River Laboratories International stock will be more than 20% underwater in next one year
41.1%
Probability that Charles River Laboratories International stock will be more than 30% underwater in next one year.
36.5%
Probability that Charles River Laboratories International stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does CRL drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Charles River Laboratories International was unfortunately bought at previous high price.
Drawdowns
Returns for CRL
Cumulative Returns on CRL
15.9%
10-Year Cumulative Returns
15.5%
7-Year Cumulative Returns
11.9%
5-Year Cumulative Returns
14.8%
3-Year Cumulative Returns
What are the long-term rolling returns for CRL?
FIve years rolling returns for Charles River Laboratories International.
Annualized Returns
Which funds bought or sold CRL recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 16.08 | 75,550 | 347,550 | 0.01% |
2023-03-10 | BAILLIE GIFFORD & CO | reduced | -0.73 | 1,401,960 | 15,552,000 | 0.02% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 58.65 | 31,985,200 | 74,256,200 | 0.08% |
2023-03-08 | Capital Asset Advisory Services LLC | reduced | -55.87 | -281,469 | 320,531 | 0.03% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -19.68 | -23,000 | 187,000 | -% |
2023-02-28 | Voya Investment Management LLC | added | 82.97 | 37,634,300 | 74,321,300 | 0.10% |
2023-02-27 | Parallax Volatility Advisers, L.P. | sold off | -100 | -110,000 | - | -% |
2023-02-24 | National Pension Service | unchanged | - | 121,461 | 948,955 | -% |
2023-02-24 | NATIXIS | sold off | -100 | -6,030,000 | - | -% |
2023-02-24 | SRS Capital Advisors, Inc. | unchanged | - | 2,405 | 24,405 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Charles River Laboratories International News
Schedule 13G FIlings of Charles River Laboratories International
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 11.71% | 5,956,960 | SC 13G/A | |
| Jan 31, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Jan 24, 2023 | blackrock inc. | 9.8% | 4,981,145 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 11.63% | 5,869,125 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G | |
| Jan 28, 2022 | blackrock inc. | 10.1% | 5,080,026 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 10.11% | 5,027,904 | SC 13G/A | |
| Jan 27, 2021 | blackrock inc. | 10.8% | 5,369,613 | SC 13G/A | |
| Jul 10, 2020 | blackrock inc. | 10.8% | 5,341,383 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 10.89% | 5,319,376 | SC 13G/A |
CRL Fair Value
Charles River Laboratories International fair value in different scenarios
The table shows the Fair Value estimates for Charles River Laboratories International for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 177.38 -8.36% | 225.18 16.34% | 309.56 59.93% | 396.77 104.99% | 458.30 136.77% |
| Current Inflation | 162.60 -16.00% | 203.18 4.97% | 273.68 41.39% | 346.61 79.07% | 397.74 105.49% |
| Very High Inflation | 144.43 -25.38% | 176.72 -8.70% | 231.55 19.63% | 288.48 49.04% | 328.06 69.49% |
Historical Charles River Laboratories International Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Charles River Laboratories International
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 08, 2023 | 4 | Insider Trading | |
| Feb 24, 2023 | 4 | Insider Trading | |
| Feb 22, 2023 | 8-K | Current Report | |
| Feb 22, 2023 | 4 | Insider Trading | |
| Feb 22, 2023 | 4 | Insider Trading | |
| Feb 22, 2023 | 4 | Insider Trading | |
| Feb 22, 2023 | 4 | Insider Trading | |
| Feb 22, 2023 | 4 | Insider Trading | |
| Feb 22, 2023 | 4 | Insider Trading | |
| Feb 22, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for CRL
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-07 | Girshick Birgit | gifted | - | - | -475 | corporate executive vp & coo |
2023-02-23 | WALLMAN RICHARD F | bought | 386,278 | 220 | 1,750 | - |
2023-02-22 | Girshick Birgit | sold (taxes) | -75,028 | 243 | -308 | corporate executive vp & coo |
2023-02-22 | LaPlume Joseph W | sold (taxes) | -77,221 | 243 | -317 | evp, corp strategy & develop |
2023-02-22 | Knell Michael Gunnar | sold (taxes) | -12,423 | 243 | -51.00 | csvp&chief accounting officer |
2023-02-22 | Parisotto Shannon M | sold (taxes) | -33,129 | 243 | -136 | cevp, disc & safety assessment |
2023-02-22 | FOSTER JAMES C | sold (taxes) | -441,890 | 243 | -1,814 | chairman, president and ceo |
2023-02-22 | Barbo William D | sold (taxes) | -69,913 | 243 | -287 | corporate executive vp & cco |
2023-02-22 | Creamer Victoria L | sold (taxes) | -44,091 | 243 | -181 | evp & chief people officer |
2023-02-16 | Girshick Birgit | sold | -815,310 | 254 | -3,205 | corporate executive vp & coo |
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
CRL Income Statement
2022-12-31CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 25, 2021 | Dec. 26, 2020 | |
| Total revenue | $ 3,976,060 | $ 3,540,160 | $ 2,923,933 |
| Costs and expenses: | |||
| Selling, general and administrative | 665,098 | 619,919 | 528,935 |
| Amortization of intangible assets | 146,578 | 124,857 | 111,877 |
| Operating income | 650,975 | 589,862 | 432,729 |
| Other income (expense): | |||
| Interest income | 780 | 652 | 834 |
| Interest expense | (59,291) | (73,910) | (86,433) |
| Other income (expense), net | 30,523 | (35,894) | 99,984 |
| Income before income taxes | 622,987 | 480,710 | 447,114 |
| Provision for income taxes | 130,379 | 81,873 | 81,808 |
| Net income | 492,608 | 398,837 | 365,306 |
| Less: Net income attributable to noncontrolling interests | 6,382 | 7,855 | 1,002 |
| Net income attributable to common shareholders | $ 486,226 | $ 390,982 | $ 364,304 |
| Earnings per common share | |||
| Basic (in dollars per share) | $ 9.57 | $ 7.77 | $ 7.35 |
| Diluted (in dollars per share) | $ 9.48 | $ 7.60 | $ 7.20 |
| Weighted-average number of common shares outstanding: | |||
| Basic (in shares) | 50,812 | 50,293 | 49,550 |
| Diluted (in shares) | 51,301 | 51,425 | 50,611 |
| Service | |||
| Total revenue | $ 3,216,904 | $ 2,755,579 | $ 2,296,156 |
| Costs and expenses: | |||
| Cost of services provided and products sold | 2,143,318 | 1,837,487 | 1,533,230 |
| Product | |||
| Total revenue | 759,156 | 784,581 | 627,777 |
| Costs and expenses: | |||
| Cost of services provided and products sold | $ 370,091 | $ 368,035 | $ 317,162 |
CRL Balance Sheet
2022-12-31CONSOLIDATED BALANCE SHEETS - USD ($) shares in Thousands, $ in Thousands | Dec. 31, 2022 | Dec. 25, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 233,912 | $ 241,214 |
| Trade receivables and contract assets, net of allowances for credit losses of $11,278 and $7,180, respectively | 752,390 | 642,881 |
| Inventories | 255,809 | 199,146 |
| Prepaid assets | 89,341 | 93,543 |
| Other current assets | 107,580 | 97,311 |
| Total current assets | 1,439,032 | 1,274,095 |
| Property, plant and equipment, net | 1,465,655 | 1,291,068 |
| Venture capital and strategic equity investments | 311,602 | 201,352 |
| Operating lease right-of-use assets, net | 391,762 | 292,941 |
| Goodwill | 2,849,903 | 2,711,881 |
| Intangible assets, net | 955,275 | 1,061,192 |
| Deferred tax assets | 41,262 | 40,226 |
| Other assets | 148,279 | 151,537 |
| Total assets | 7,602,770 | 7,024,292 |
| Current liabilities: | ||
| Accounts payable | 205,915 | 198,130 |
| Accrued compensation | 197,078 | 246,119 |
| Deferred revenue | 264,259 | 219,703 |
| Accrued liabilities | 219,758 | 228,797 |
| Other current liabilities | 204,575 | 140,436 |
| Total current liabilities | 1,091,585 | 1,033,185 |
| Long-term debt, net and finance leases | 2,707,531 | 2,663,564 |
| Operating lease right-of-use liabilities | 389,745 | 252,972 |
| Deferred tax liabilities | 215,582 | 239,720 |
| Other long-term liabilities | 174,822 | 242,859 |
| Total liabilities | 4,579,265 | 4,432,300 |
| Commitments and contingencies | ||
| Redeemable noncontrolling interest | 42,427 | 53,010 |
| Equity [Abstract] | ||
| Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding | 0 | 0 |
| Common stock, $0.01 par value; 120,000 shares authorized; 50,944 shares issued and outstanding as of December 31, 2022 and 50,480 shares issued and outstanding as of December 25, 2021 | 509 | 505 |
| Additional paid-in capital | 1,804,940 | 1,718,304 |
| Retained earnings | 1,432,901 | 980,751 |
| Treasury stock, at cost, zero shares as of December 31, 2022 and December 25, 2021 | 0 | 0 |
| Accumulated other comprehensive loss | (262,057) | (164,740) |
| Total equity attributable to common shareholders | 2,976,293 | 2,534,820 |
| Noncontrolling interests (nonredeemable) | 4,785 | 4,162 |
| Total equity | 2,981,078 | 2,538,982 |
| Total liabilities, redeemable noncontrolling interests and equity | $ 7,602,770 | $ 7,024,292 |
| Beginning balance (in shares) | 0 | 0 |